关于向银行申请综合授信额度的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 江西阳光乳业股份有限公司（以下简称"公司"）于2025年4月16日召开第 六届董事会第六次会议，审议通过了《关于向银行申请综合授信额度的议案》， 具体情况如下： 证券代码：001318 证券简称：阳光乳业 公告编号：2025-010 江西阳光乳业股份有限公司 特此公告! 为满足公司经营发展的资金需求，公司拟向商业银行申请不超过人民币4亿 元的综合授信额度，用于补充公司流动资金，期限3年，期间授信到期的可在不 超过总额度内循环授信。上述授信额度不等于公司的实际融资金额，实际融资金 额应在授信总额内，以银行与公司实际发生的融资金额为准。 董事会授权董事长在上述授信额度及期限内办理银行融资相关手续，并签 署相关法律文件。 2025年4月16日 江西阳光股份股份有限公司董事会 ...

江西阳光乳业股份有限公司 董事会审计委员会对会计师事务所 履行监督职责情况报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司 治理准则》《国有企业、上市公司选聘会计师事务所管理办法》等规定和要 求，江西阳光乳业股份有限公司（以下简称"公司"）董事会审计委员会 （以下简称"审计委员会"）本着勤勉尽责的原则，恪尽职守认真履职，对 公司审计机构大信会计师事务所（特殊普通合伙）（以下简称"大信所"） 2024 年审计工作履行了监督职责，现将情况汇报如下： 一、资质审查情况 公司董事会审计委员会对大信所及项目人员的专业资质、业务能力、投资 者保护能力、诚信状况、独立性、审计工作情况及其执业质量等进行了核查和 评价，认为其具备为公司提供审计工作的资质和专业能力，能够满足公司审计 工作的要求。 （2）在审计期间，董事会审计委员会与大信所进行了充分的沟通，听取了 其关于公司审计内容的相关调整事项、审计工作过程中的相关问题。在了解相 关情况后及时解决问题，并督促其在约定时限内提交审计报告，确保审计工作 规范有序。同时，董事会审计委员会按照相关规定要求，在大信所出具 2024 年 年度审计报告初步审计意见后，审 ...

证券代码：001318 证券简称：阳光乳业 公告编号：2025-011 江西阳光乳业股份有限公司 关于变更部分募集资金用途及募集资金项目延期的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、变更募集资金投资项目的概述 （一）募集资金基本情况 经中国证券监督管理委员会《关于核准江西阳光乳业股份有限公司首次公开发行股票的批 复》（证监许可（2022）649号）核准，江西阳光乳业股份有限公司（以下简称：公司）于2022 年5月于深圳证券交易所向社会公众公开发行人民币普通股(A股)7,070万股，发行价为9.46元/ 股，募集资金总额为人民币668,822,000.00元，扣除承销及保荐费用人民币46,497,249.05元， 余额为人民币622,324,750.95元，另外扣除中介机构费和其他发行费用人民币21,525,150.95元， 实际募集资金净额为人民币600,799,600.00元。公司已与保荐机构、存放募集资金的商业银行 签署了《募集资金三方监管协议》和《募集资金四方监管协议》，设立了募集资金专项账户， 对募集资金实行专户存储。截至本公告披露日 ...

证券代码：001318 证券简称：阳光乳业 公告编号：2025-006 江西阳光乳业股份有限公司 关于2025年日常关联交易预计的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、 日常关联交易基本情况 （一） 关联交易概述 江西阳光乳业股份有限公司（以下简称"公司"）由于日常经营需要预计2025 年将与关联方江西阳光乳业集团有限公司、安徽华好生态养殖有限公司、安徽华 好商贸有限公司、高亦农、郭智、江西阳光乳业电商科技有限公司、江西阳光宜 佳商务服务有限公司发生日常关联交易，关联交易总金额不超过8,740.00万元， 上年度公司与关联方发生的日常关联交易总额为7,409.41万元。 2025年4月16日，公司第六届董事会第六次会议审议通过了《关于2025年日常 关联交易预计的议案》，关联董事胡霄云、高金文、梅英在本议案中回避表决。 第六届监事会第六次会议审议通过了《关于2025年日常关联交易预计的议案》， 关联监事刘永平在议案中回避表决。本次关联交易需提交公司股东大会进行审议， 关联股东江西阳光乳业集团有限公司、南昌致合企业管理中心（有限合伙）应回 避 ...

证券代码：001318 证券简称：阳光乳业 公告编号：2025-014 江西阳光乳业股份有限公司 关于召开 2024 年度股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 江西阳光乳业股份有限公司（以下简称"公司"）第六届董事会第六次会议 审议通过了《关于召开 2024 年度股东大会的议案》，决定于 2025 年 5 月 8 日召 开公司 2024 年度股东大会，现将会议有关事项通知如下： 一、召开会议的基本情况 1、股东大会届次：2024 年度股东大会 2、股东大会的召集人：公司第六届董事会 3、会议召开的合法、合规性：本次股东大会会议的召开符合有关法律、行 政法规、部门规章、规范性文件和《公司章程》的规定。 4、会议召开日期和时间 （1）现场会议时间：2025 年 5 月 8 日（星期四）11:30 （2）网络投票时间：2025 年 5 月 8 日（星期四） 通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 5 月 8 日 9：15-9：25、9：30-11：30、13：00-15：00； 通过深圳证券交易所互联网系统(htt ...

一、 监事会会议召开情况 江西阳光乳业股份有限公司（以下简称"公司"）第六届监事会第六次会议 通知于 2025 年 4 月 6 日以电子邮件的形式发出，并于 2025 年 4 月 16 日在公司 办公楼会议室以现场会议的方式召开。本次会议由公司监事会主席肖爱国先生召 集并主持，应出席监事 3 人，实际出席监事 3 人，全部本人出席。 本次会议的召集和召开符合《公司法》等法律、行政法规、规范性文件以及 《公司章程》的规定。 证券代码：001318 证券简称：阳光乳业 公告编号：2025-004 江西阳光乳业股份有限公司 第六届监事会第六次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 二、会议审议情况 1、审议通过《2024 年度监事会工作报告》 具体内容详见同日在巨潮网（www.cninfo.com.cn）披露的《2024 年度监事 会工作报告》。 表决结果：3 票同意，0 票反对，0 票弃权 本议案需提交公司 2024 年度股东大会审议。 2、审议通过《2024 年度财务决算报告》 具体内容详见同日在巨潮网（www.cninfo.com.cn） ...

证券代码：001318 证券简称：阳光乳业 公告编号：2025-003 江西阳光乳业股份有限公司 第六届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、 董事会会议召开情况 江西阳光乳业股份有限公司（以下简称"公司"）第六届董事会第六次会议 通知于 2025 年 4 月 6 日以直接送达和电子邮件的形式发出，并于 2025 年 4 月 16 日在公司办公楼会议室以现场会议的方式召开。本次会议由公司董事长胡霄 云先生召集并主持，应出席董事 7 人，实际出席董事 7 人，全部本人出席。公司 监事及高级管理人员列席会议。 本次会议的召集和召开符合《公司法》等法律、行政法规、规范性文件以及 《公司章程》的规定。 二、 会议审议情况 1、审议通过《2024 年度董事会工作报告》 具体内容详见同日在巨潮网（www.cninfo.com.cn）披露的《2024年度董事会 工作报告》。依据独立董事出具的《独立董事关于2024年度独立性情况的自查报 告》，董事会编写了《董事会关于独立董事独立性自查情况的专项报告》一同披露。 公司独立董事陈荣先生、顾 ...

江西阳光乳业股份有限公司 关于 2024 年度利润分配预案的公告 一、 审议程序 江西阳光乳业股份有限公司（以下简称"公司"）于 2025 年 4 月 16 日召开 第六届董事会第六次会议，以 7 票同意、0 票反对、0 票弃权、0 票回避审议通 过了《关于 2024 年度利润分配预案的议案》，尚需提交 2024 年度股东大会审议。 二、利润分配的基本情况 证券代码：001318 证券简称：阳光乳业 公告编号：2025-005 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 | 项目 | 本年度 | 上年度 | 上上年度 | | --- | --- | --- | --- | | 现金分红总额（元） | 50,878,800 | 45,225,600 | 42,399,000 | | 回购注销总额（元） | 0 | 0 | 0 | | 归属于上市公司股东的净利 | 114,564,893.06 | 115,823,647.33 | 110,889,403.79 | | 润（元） | | | | | 合并报表本年度末累计未分 | | 433,930,717.91 ...

Dividend Distribution - The company plans to distribute a cash dividend of 1.8 yuan per 10 shares to all shareholders, based on a total of 282,660,000 shares[4]. - The cash dividend amount is subject to adjustment if there are changes in total share capital before the equity distribution registration date[197]. - The cash dividend distribution is based on a total share capital of 28,266,000 shares[197]. - The total distributable profit for 2024 is 433,930,717.91 yuan, with the cash dividend amounting to 100% of the profit distribution total[195]. - The company reported a net profit of 114,564,893.06 yuan for 2024 after accounting for statutory surplus reserves[196]. - The remaining undistributed profits will be carried forward to future periods, with no stock dividends or capital reserve increases planned[197]. - The company has not made any adjustments to its profit distribution policy during the reporting period, ensuring compliance with regulations[193]. Financial Performance - The company's operating revenue for 2024 was ¥519,418,156.94, a decrease of 8.86% compared to ¥569,933,839.82 in 2023[24]. - The net profit attributable to shareholders for 2024 was ¥114,564,893.06, down 1.09% from ¥115,823,647.33 in 2023[24]. - The net profit after deducting non-recurring gains and losses increased by 2.88% to ¥119,567,796.33 in 2024 from ¥116,224,472.31 in 2023[24]. - The net cash flow from operating activities decreased by 17.23% to ¥139,542,716.05 in 2024 from ¥168,586,511.39 in 2023[24]. - Total assets at the end of 2024 were ¥1,488,952,832.62, reflecting a 4.31% increase from ¥1,427,404,152.93 at the end of 2023[24]. - The net assets attributable to shareholders increased by 5.19% to ¥1,405,451,999.56 at the end of 2024 from ¥1,336,112,706.50 at the end of 2023[24]. - The company's revenue for 2024 was CNY 519,418,156.94, a decrease of 8.87% compared to CNY 569,933,839.82 in 2023[64]. - The distribution model accounted for 82.63% of total revenue in 2024, generating CNY 429,210,128.76, down 10.97% from the previous year[64]. - Direct sales revenue increased by 2.68% to CNY 90,208,028.18, representing 17.37% of total revenue in 2024[64]. Market and Industry Outlook - In 2024, China's dairy industry is facing overall pressure, with national milk production expected to decline by 2.8% year-on-year, and large-scale dairy farms reducing their cattle inventory by 200,000 to 300,000 heads[35]. - The average per capita dairy consumption in China is approximately one-third of the world average and about half of that in developing countries, indicating significant future growth potential[35]. - According to the "Chinese Dietary Guidelines (2022)", the recommended daily intake of dairy products has increased to 300-500 grams, encouraging higher consumption levels[40]. - The dairy industry is focusing on quality improvement through advanced production technologies and strict quality management systems, enhancing consumer confidence and international competitiveness[36]. - The government is promoting dairy consumption through policies like the "Healthy China 2030" plan and the "National Nutrition Plan (2017-2030)", aiming to enhance the dairy industry's development[41]. - The overall growth rate of the Chinese dairy industry is expected to slow down significantly in 2024, with potential negative growth in the following years due to demographic changes and consumption diversification[134]. - Despite short-term challenges, the long-term outlook for the dairy industry remains positive, driven by low per capita dairy consumption compared to global averages[134]. Product Development and Innovation - The company launched new products including A2-β casein concentrated milk and "Old Nanchang" osmanthus wine yogurt, which received positive consumer feedback[63]. - The company is developing a new high-protein, high-calcium yogurt using nanofiltration technology, which is expected to expand the consumer base and increase product variety[110]. - The company has completed the development of a new black sugar ginger soup, which is now in production and aims to become a mainstream product[112]. - The company plans to invest in the research and development of at least 10 new products and projects for 2025, with a target of launching no less than 15 new products and phasing out at least 10 old products, allocating over 3% of revenue to R&D expenses[137]. Operational Efficiency and Cost Management - The company's main business cost for 2024 is approximately ¥322.79 million, accounting for 99.99% of total operating costs, a decrease from ¥362.71 million in 2023[79]. - The average purchase price of whole milk powder decreased by 30.73% in 2024, resulting in a cost reduction of approximately ¥4.86 million[70]. - The company's operating costs decreased by 11.00% to ¥322,804,211.96, attributed to a decline in raw material procurement prices[90]. - The gross profit margin for product sales reached 38%, an increase of 1.5 percentage points compared to 2023, despite a decline in overall revenue[92]. - The company has established a comprehensive sales network, including home delivery, supermarkets, and specialty stores, enhancing customer loyalty and repeat purchase rates[81]. - The cold chain logistics system developed by the company ensures product quality and timely delivery, crucial for maintaining consumer trust in low-temperature products[82]. Risk Management and Compliance - The company is facing risks related to insufficient milk supply and price fluctuations, with measures in place to increase self-supply and establish long-term contracts with suppliers to mitigate these risks[148]. - The fundraising investment project is expected to significantly increase fixed assets and production capacity, but there are risks of not meeting expected returns due to market changes or management issues, which could lead to a substantial decline in net profit[149]. - Changes in tax policies could adversely affect the company's performance, but the company aims to enhance core competitiveness and optimize product structure to mitigate these impacts[151]. - The company has established a robust internal control system to mitigate operational risks, focusing on areas such as food safety and financial management[144]. - The company has received a standard unqualified opinion from the auditor regarding internal controls, ensuring compliance with relevant laws and regulations[199]. Governance and Management - The company maintains an independent human resources management system, with senior management not holding positions in the controlling shareholder's other enterprises[164]. - The company has established an independent financial department with a standardized accounting system, ensuring independent financial decision-making[167]. - The board of directors and senior management have been in their positions since December 16, 2020, with terms ending on December 18, 2026[171]. - The company has a total of 12 directors and supervisors, with a diverse range of expertise in various fields[182]. - The company has a structured remuneration decision-making process that involves proposals from independent directors and approval from the board and shareholders[180]. - The company has a commitment to transparency in its remuneration practices, adhering to its established compensation policies[180]. Employee and Community Engagement - The total number of employees at the end of the reporting period is 1,011, with 714 in the parent company and 297 in major subsidiaries[189]. - The company has established a comprehensive employee training system to enhance the overall quality and capabilities of its workforce[192]. - The company actively promoted its brand, hosting over 200 community events and participating in more than 10 major exhibitions throughout the year[94]. - The company has 57 retired employees for whom it bears costs[189].

Financial Performance - The company's operating revenue for Q1 2025 was ¥104,943,144.28, a decrease of 3.62% compared to ¥108,881,781.06 in the same period last year[5] - Net profit attributable to shareholders was ¥22,059,641.87, representing an increase of 2.58% from ¥21,504,922.08 year-on-year[5] - Basic earnings per share for Q1 2025 were ¥0.0780, up 2.50% from ¥0.0761 in the same period last year[5] - Net profit for the current period increased by 9.2% to ¥21,502,375.38 compared to ¥19,689,324.27 in the previous period[18] - Earnings per share (EPS) for the current period was ¥0.0780, up from ¥0.0761 in the previous period[18] Cash Flow and Liquidity - The net cash flow from operating activities increased by 458.28%, reaching ¥20,993,336.25, compared to a negative cash flow of ¥5,859,400.09 in the previous year[9] - The net cash flow from operating activities was $20,993,336.25, a significant improvement from a negative cash flow of $5,859,400.09 in the previous period, indicating a recovery in operational efficiency[20] - The net cash flow from investment activities was $8,141,348.87, recovering from a negative cash flow of $4,680,728.28 previously, showcasing effective asset management[20] - The net increase in cash and cash equivalents for the period was $29,134,685.12, contrasting with a decrease of $10,540,128.37 in the previous period, indicating improved liquidity[21] - The ending balance of cash and cash equivalents reached $581,678,770.07, up from $477,347,078.17 at the end of the previous period, reflecting a stronger cash position[21] Assets and Equity - Total assets at the end of the reporting period were ¥1,501,614,360.67, reflecting a growth of 0.85% from ¥1,488,952,832.62 at the end of the previous year[5] - Shareholders' equity attributable to the parent company increased by 1.57% to ¥1,427,511,641.43 from ¥1,405,451,999.56[5] - Total assets increased to ¥1,501,614,360.67 from ¥1,488,952,832.62, reflecting a growth of 0.9%[15] - Total equity attributable to shareholders increased to ¥1,427,511,641.43 from ¥1,405,451,999.56, marking a growth of 1.6%[15] Costs and Expenses - Total operating costs decreased by 6.0% to ¥82,148,198.66 from ¥87,235,482.44, with operating costs specifically down by 4.2% to ¥67,586,957.14[17] - Research and development expenses decreased significantly by 37.9% to ¥3,166,228.24 from ¥5,096,005.31[17] - Cash paid for purchasing goods and services decreased to $51,618,125.65 from $77,319,695.23, suggesting improved cost management[20] Other Financial Aspects - The company reported a loss of ¥744,008.99 from the disposal of non-current assets, primarily due to losses from biological assets[7] - Government subsidies recognized in the current period amounted to ¥741,003.18, contributing positively to the financial results[7] - The company has strengthened its management of procurement payments, which significantly improved cash flow from operations[9] - The first quarter report was not audited, which may affect the perception of financial reliability[22] - The cash flow statement for the current period is yet to be detailed, indicating potential areas for further analysis[19] - The total number of ordinary shareholders at the end of the reporting period was 23,892[11] - The company reported a credit impairment loss of ¥581.81, contrasting with a gain of ¥24,320.34 in the previous period[18] - Cash received from sales of goods and services was $120,093,669.14, slightly up from $119,958,994.41, indicating stable revenue generation[20] - Cash received from tax refunds increased to $1,607.85 from $148.16, indicating better tax recovery processes[20] - The company did not report any cash inflows from financing activities, indicating a focus on internal funding sources[21]